Sign in
Taking people in United StatesPhase 1/2

Tests CD40L-boosted immune cells in advanced melanoma patients

Tests CD40L-boosted tumor-infiltrating lymphocytes in adults with advanced melanoma.

Key facts

Who runs it
H. Lee Moffitt Cancer Center and Research Institute
Where
Tampa, United StatesSee the site
Trial code
Registry title
Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma
Status
Recruiting
Phase
Phase 1/2
People taking part
36 people, planned
Started
3 Dec 2025
Expected to end
May 2030
Type of study
Interventional, 4 groups
Treatments tested
  • Cyclophosphamide
  • Fludarabine
  • Interleukin-2
  • TIL Product
Record updated
26 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with advanced melanoma that cannot be removed by surgery or has spread, and whose disease got worse after standard treatment. It tests TIL cells made from the patient's own tumor.

Age
18 years or older. The preferred range is 18-75 years. Some people over 75 can join if they have no major health problems.
Sex
All sexes can join.
Disease stage
Melanoma that cannot be removed by surgery (Stage III/IV) or has spread. Types: skin non-acral, skin acral, mucosal, or eye (uveal, iris, conjunctival) melanoma. At least one tumor must be reachable by surgery and one measurable after surgery.
Earlier treatment
Must have failed, not responded to, or not tolerated at least one standard treatment. Any systemic therapy must have ended at least 4 weeks before lymphodepleting therapy. Side effects from earlier treatment must be Grade 1 or milder, except hair loss and vitiligo.
Biomarker or test result
No specific marker is required. People must test negative for HIV, hepatitis B and hepatitis C.

Main reasons for not taking part

  • Heart disease or heart rhythm problems, unless a cardiac stress test and heart doctor's review show low or acceptable risk
  • HIV/AIDS or another immune system deficiency
  • Pregnancy; breastfeeding must stop if the mother joins
  • Steroids above 10 mg prednisone daily, or other immune-suppressing drugs
  • Active infection needing antibiotics, or active autoimmune disease needing immune-suppressing treatment

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Participants must have histologically confirmed, unresectable (Stage III/IV) or metastatic melanoma as follows: Cutaneous, non-acral, melanoma (including melanoma of unknown primary); Cutaneous acral melanoma; Mucosal melanoma; Ocular melanoma (including uveal, iris, conjunctival melanoma)
  • Participants must have failed, be refractory to, or unable to tolerate at least one line of standard of care in the opinion of the Investigator. For participants with cutaneous non-acral melanoma, standard of care therapy includes a PD-1/L1 or combination therapy with anti-PD1 and anti-CTLA4 or combination therapy of anti-PD1 and anti-LAG3 or if BRAF V600 activating mutation positive, a BRAF ± MEK inhibitor. Participants are allowed to be enrolled in this trial if they failed one line of any of those standards of care therapy regimens
  • Any systemic therapy, including anti-cancer monoclonal antibodies, must have been completed at least 4 weeks from the start of lymphodepleting therapy, and any prior therapy-related AEs must have resolved to Grade ≤ 1 except for alopecia and vitiligo
  • Participants must be ages ≥18. Additionally, participants who are ≥ 65 years of age may need to undergo a cardiology evaluation including a cardiac stress test or coronary computed tomography after which they must be deemed to be low/acceptable risk. This cardiac evaluation may be omitted for patients who underwent testing within 6 months and have no interval change in cardiopulmonary clinical status. Note 1: Cardiac stress test may be omitted for patients ≥65 years old (y/o) who are fully functional with no relevant medical comorbidities and are able to carry ≥4 METS activities at baseline. For patients who demonstrate abnormal cardiac stress test cardiac evaluation by cardiologist will be done and if deemed low acceptable risk, will be allowed to participate in this trial per PI discretion. Cardiac stress test may be indicated for any patient <65 y/o who have relevant medical comorbidities or demonstrate clinically worrisome symptoms. Note 2: While age preference will be between 18-75 years, this study allows age >75 years if the patient meets eligibility criteria and demonstrates no significant medical comorbidities per PI
  • ECOG performance status of 0 or 1
  • Participants must have adequate organ and marrow function as defined within the protocol
  • Seronegative for Human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen, and hepatitis C (HCV) antibody (if HCV antibody positive, must be tested for HCV RNA, which must be negative to be eligible)
  • Participants with brain metastases are eligible provided that the brain metastases have been successfully treated with stereotactic radiosurgery or resection and clinically stable for at least 4 weeks (±14 days). Note: Participants who develop brain metastases after tumor harvest and/or lymphodepleting therapy will be allowed to remain on study and may proceed with cell therapy after undergoing definitive radiation therapy and/or surgery. For those participants who develop brain metastases during lymphodepleting therapy and undergo definitive radiation therapy and/or surgery careful decision will be made to proceed with TIL infusion after discussion with treating physician, neurosurgeon, radiation oncologist and PI
  • Women of child-bearing potential must have a negative pregnancy test
  • The effects of CD40L-augmented TIL on the developing human fetus are unknown. For this reason and because TIL agents, as well as other therapeutic agents used in this trial including IL-2 are known to be teratogenic, both males and females of childbearing potential must be willing to practice birth control starting with screening through 1 year after the last study drug is administered for females or 6 months for males
  • Should a woman become pregnant or suspect she is pregnant while she or her partner are participating in this study, she should inform her treating physician immediately
  • Ability to understand and the willingness to sign a written informed consent document
  • Participants should have at least one surgically accessible lesion for tumor harvest for preparation of TIL, and at least one RECIST v1.1 measurable lesion after tumor harvest to follow for response assessment. Note: Tumor harvest lesion will be considered as target lesion if after harvest remaining portion of tumor meets RECIST v1.1 measurable lesion criteria

Who cannot take part

  • Participants taking systemic steroid therapy (other than replacement therapy or prednisone equivalent of ≤10mg daily) or therapy with any immunosuppressive medications such as mycophenolate mofetil (MMF). Participants who require more than 10mg of prednisone or equivalent other steroid therapy should taper their steroid therapy to 10 mg prednisone 1 week prior to planned first interventional drug therapy (lymphodepleting therapy). Participants who are on baseline replacement therapy or prednisone equivalent of ≤10mg daily and require stress doses of steroid therapy will be allowed to receive stress dose steroids during the trial interventions. Participants who require dapsone for pneumocystis pneumonia (PCP) prophylaxis during TIL therapy are eligible
  • Participants with active autoimmune diseases currently requiring systemic treatment with immunosuppressive doses of corticosteroids (>10 mg of prednisone-equivalent daily dosing), immunosuppressive biologic agents, or disease modifying antirheumatic drug agents (DMARDs)
  • Patients who received prior live cell therapy are excluded, unless express written permission is provided by the clinical PI
  • Participants with either a primary immunodeficiency disorder (i.e., severe combined immunodeficiency syndrome) or acquired immunodeficiency disorders (such as HIV/AIDS)
  • Participants who have a history of severe immediate hypersensitivity reaction to the study agents including cyclophosphamide, fludarabine, or IL-2 or any of their constituents
  • Participants who, in the opinion of the Investigator, have a medical condition that would subject the patient to prohibitive risk by participation in this study, or who may be unable to safely complete tumor harvest, lymphodepletion regimen, TIL infusion, or aldesleukin administration
  • Participants with active infections requiring antibiotics
  • Participants, regardless of age, who have a current or past medical history of ischemic heart disease, or clinically significant atrial or ventricular rhythm abnormality are excluded unless they undergo a cardiac stress test and cardiology clearance examination and are determined to be low or acceptable risk
  • Participants with a left ventricular ejection fraction (LVEF) ≤ 45% or New York Heart Association (NYHA) functional classification > 1
  • Pregnant women are excluded from this study because the agents used in this study have teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with CD40L-augmented TIL or the other agents in the study, breastfeeding should be discontinued if the mother is enrolled in the study
  • Forced expiratory volume (FEV1) ≤ 60% of predicted value and DLCO (corrected) < 60% of predicted value. Participants who underwent pulmonary function testing within 6 months of screening may omit PFTs if they demonstrate stable cardiopulmonary status

Where in United States

  • Moffitt Cancer CenterTampa, United StatesContact: Lilit Karapetyan, MD (principal investigator)Taking people

About the trial

What the trial wants to find out

This is a phase I/II clinical trial of a single dose of CD40L-augmented TIL administered in patients with advanced melanoma (Cohort 1: Cutaneous acral melanoma, cutaneous non-acral melanoma, (n=26); Cohort 2: Mucosal melanoma, uveal melanoma, (n=10)). Patients will undergo an excision of a readily accessible tumor for preparation of TIL. Eligible patients with progressive disease after standard of care therapy will undergo lymphodepletion with cyclophosphamide and fludarabine followed by CD40L-augmented TIL and standard of care bolus dose interleukin-2 (short-course IL-2).

The 4 groups in the trial

  • Cohort 1: Phase I safety trialTreatment being tested

    Participants will receive a single dose of CD40L-Augmented TIL. Toxicity will be evaluated at every 4 patients. The study may enroll 16-20 patients to reach 12 TIL safety evaluable patients.

    Treatment: Cyclophosphamide, Fludarabine, Interleukin-2, and TIL Product

  • Cohort 1: Phase II efficacy trialTreatment being tested

    If there are 2 responders or more, the trial will continue to enroll additional 14 patients in the 2nd stage.

    Treatment: Cyclophosphamide, Fludarabine, Interleukin-2, and TIL Product

  • Cohort 2: Rare melanoma subtypesTreatment being tested

    Cohort 2 will include n=10 patients with the rare melanoma histological subtypes of mucosal or uveal melanoma and will be used to assess feasibility and toxicity of the treatment in those rare melanoma subtypes.

    Treatment: Cyclophosphamide, Fludarabine, Interleukin-2, and TIL Product

  • Cohort 3: TIL derived from core needle biopsy samples (all subtypes)Treatment being tested

    Cohort 3 will include 12 patients with any subtype of melanoma whose TILs are manufactured from CNB specimens to assess the feasibility of this process.

    Treatment: Cyclophosphamide, Fludarabine, Interleukin-2, and TIL Product

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase I/II Clinical Trial of CD40L-augmented Tumor Infiltrating Lymphocytes (TIL) for Patients With Advanced Melanoma
Plain-language title
Tests CD40L-boosted immune cells in advanced melanoma patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
26 June 2026